Abstract Reelin is an extracellular glycoprotein involved in key cellular processes in developing and adult nervous system, including regulation of neuronal migration, synapse formation, and plasticity. Most of these roles are mediated by the intracellular phosphorylation of disabled-1 (Dab1), an intracellular adaptor molecule, in turn mediated by binding Reelin to its receptors. Altered expression and glycosylation patterns of Reelin in cerebrospinal and cortical extracts have been reported in Alzheimer's disease. However, putative changes in Reelin are not described in natural prionopathies or experimental models of prion infection or toxicity. With this is mind, in the present study, we determined that Reelin protein and mRNA levels increased in CJD human samples and in mouse models of human prion disease in contrast to murine models of prion infection. However, changes in Reelin expression appeared only at late terminal stages of the disease, which prevent their use as an efficient diagnostic biomarker. In addition, increased Reelin in CJD and in in vitro models does not correlate with Dab1 phosphorylation, indicating failure in its intracellular signaling. Overall, these findings widen our understanding of the putative changes of Reelin in neurodegeneration.
Introduction
Reelin is an extracellular matrix protein essential for proper neuronal migration in laminated areas of the developing brain [1, 2] . In adulthood, Reelin has been localized in synaptic terminals (especially from GABAergic interneurons) and implicated in neuronal plasticity [3, 4] . In fact, Reelin actively participates as a key actor in several neural processes such us cell survival [5] and synaptic plasticity [6] [7] [8] as well as in pathological conditions such as ischemia [9, 10] and neurodegeneration [11] [12] [13] . These results point to the maintenance of Reelin protein levels as crucial for correct homeostatic balance in developing and adult nervous system. In neural tissue, Reelin binds to Apolipoprotein E receptor 2 (ApoER2) and Very Low-Density Lipoprotein Receptor (VLDLR), triggering tyrosine phosphorylation of disabled-1 (Dab1), a cytoplasmic adaptor protein, by kinases of the Src family [14] [15] [16] [17] . Following phosphorylation, Dab1 protein recruits the p85α subunit of phosphatidylinositol-3 kinase (PI3K), stimulating AKT-phosphorylation, glycogen synthase kinase 3β (GSK3β), and CrkL [18, 19] .
Reelin protein levels in the brain could be modified by several factors such as hormones [20] [21] [22] [23] [24] , oxidative stress [25] , perinatal stress [26] , and exercise [27] . Some of these conditions (e.g., hormone misbalance and oxidative stress) are common features in diseases such as schizophrenia [28, 29] and autism [30] , as well as neurodegenerative diseases such as Alzheimer's disease [31, 32] and prionopathies [33] . Indeed, Reelin protein levels are altered in schizophrenia [34] and autism [35] as well as in Alzheimer's disease [36] [37] [38] . However, very few data have been reported concerning Creutzfeldt-Jakob disease (CJD) or related models of infective transmissible spongiform encephalopathies (TSEs).
Decreased Reelin levels has been reported in aging [39, 40] , mild cognitive dementia, and Alzheimer's disease [36, 41, 42] . Although a low number of Reelin-positive cells have been reported in aged brains, the Reelin decrease in Alzheimer's disease is likely associated with their presence in senile plaques enriched in aggregated β-amyloid [24, 43, 44] . In fact, it has been suggested that histologically [39] and biochemically [12] , Reelin binds to oligomeric β-amyloid preventing its accumulation in senile plaques. This is in contrast to other studies indicating increased levels of Reelin in late stages (Braak stages III-VI) of Alzheimer's disease [38] . Nonetheless, current studies suggest that reduced levels of Reelin in Alzheimer's disease increases the amyloid burden observed in the disease [7, 12, 45] . In addition, a recent study reports that Reelin produced in the presence of aggregated β-amyloid showed altered glycosylation [46] and therefore was a nonfunctional protein [11] . Thus, the combination of low protein levels and non-functional Reelin may constitute a vicious circle that promotes the progression of the cognitive impairment in Alzheimer's disease by diminishing synaptic function [13, 47] and cytoskeletal stability [11] .
As indicated above, very few data on Reln mRNA or protein levels are reported in Creutzfeldt-Jakob disease or infective prionopathies. In fact, only a recent study analyzing changes in mRNA expression by microarrays in RMLinfected cerebellar organotypic cultures indicated a slight decrease in Reln mRNA at late stages (38 and 45 days) postinfection [48] . This decrease seemed likely to be associated with the relevant granule cell death triggered by the RML infection. In a previous study [49] , we determined that mimetic peptides in aggregated form of the human sequence of the cellular prion protein (PrP 106-126 ) were able to increase the phosphorylation of Dab1. In parallel, our studies also pointed to an increase in Dab1 phosphorylation and degradation in CJD patients, especially in those with prion type I and Met/ Met 129 polymorphism [50] . Thus, high levels of p-Dab1 leading to low levels of Dab1 rely on low numbers of β-amyloid plaques [50] .
Taking this into account and as natural follow-up to our previous studies, we aimed to explore in the present study the putative changes of Reelin levels in prionopathies employing cytotoxicity models using primary neuronal cultures, prion-inoculated mice, and human sporadic CJD postmortem samples. Results demonstrate that neurons incubated with mimetic prion peptides increased Reelin expression likely by reactive oxygen species (ROS) production. In addition, Reelin and Reln mRNA are increased in post-mortem samples of CJD patients as well as in CJD-infected Tg340 mice in contrast to mice infected with mouse prions.
Materials and Methods

Mouse Strains and Genotyping
Adult male C57Bl6/129sv-Prnp 0/0 (B6129 Prnp . Specific primers to Prnp genotyping were designed in our laboratory based on the original P3 and P10 primers as described [51] : neo: 5′ -gccttctatcgccttcttgac-3′; 3′ NCnew: 5′-gctacaggtggataacccctc-3′ and P10new: 5′-cataatcagtggaacaagccc-3′. 40 cycling condition were 45″ 95°C; 45″ 62°C; 1′ 72°C, followed by a final extension at 72°C for 5 min. Prnp-overexpressing mice (Tga20) were purchased from EMMA (Monterotondo, Italy). They were generated as described by Marek et al. [52] and backcrossed in our lab with B6.129 Prnp 0/0 mice for 7 generations. For Tga20 mice, the transgene was detected using primers specific to the Tg20 allele 5′-caaccgacgtgaagcattctgccta-3′ and 5′-cctgggactccttctg gtaccgggtgacgc-3′ as indicated [53] . All experiments were performed under the guidelines and protocols of the Ethical Committee for Animal Experimentation (CEEA) of the University of Barcelona, and the protocol for the use of animals in this study was reviewed and approved by the CEEA of the University of Barcelona (CEEA approval no. 276/16 and 141/15).
Mice Inoculated with Different Prion Strains
As model of mouse prion diseases, we used B6.129 Prnp +/+ or C57BL/6J intracranially inoculated with two different mouse-adapted prion strains (22L, Mo-BSE) or with GPI-anchorless PrP SC as previously described [54, 55] . As mouse model of sCJD, we used the Tg340 mouse line inoculated with sCJD prions [56] . Tg340 mice were intracranially inoculated with an sCJD isolate obtained from the UK CJD reference center in Edinburgh [55] . Briefly, 6-to 10-week-old female mice were anesthetized and inoculated with 2 mg of brain equivalent (20 μl of a 10 % brain homogenate) in the right parietal lobe using a 25-gauge disposable hypodermic needle. The mice were observed daily and their neurological status was assessed weekly. When clinically progressive TSE disease was evident, the animals were killed and their brains collected. Brains from those animals were dissected and separated brain zones were frozen at −80°C. 
Human CJD Cases
The brains of 26 patients with sporadic CJD were obtained from 3 to 8 h after death and immediately prepared for morphological and biochemical studies. The main clinical and pathological characteristics are summarized in Table 1 . For biochemical studies, samples of the frontal cortex were frozen in liquid nitrogen and stored at −80°C until use. The standard neuropathological study was carried out on de-waxed 4-μm thick paraffin sections of several brain regions (see [50] for description).
Primary Embryonic Neuronal Cultures
E15.5-16.5 mouse embryo brains were dissected and washed in ice-cold 0.1 M PBS containing 6.5 mg/ml glucose. The meninges were removed and the cortices isolated. Tissue pieces were trypsinized for 15 min at 37°C. After the addition of horse serum and centrifugation, the cells were dissociated by trituration in 0.1 M PBS containing 0.025 % DNAse with a Prion protein fragments 106-126 (human) and scrambled prion peptide were from Sigma. Peptides (1 μg/ μl) were dissolved in PBS 0.1 M and allowed to spontaneously aggregate at room temperature for 5 h and checked at electron microscopy. After aggregation, PrP or scrambled peptides were added to the cortical cultures, which were incubated over a range of times from 30 min to 4 days. Afterward, the culture medium was collected at 4°C and peptide-treated cells were scraped in homogenization buffer containing 150 mM NaCl, 1 mM EDTA, 10 % glycerol, 1 % Triton X-100, protease inhibitor cocktail (Roche Farma), and phosphatase inhibitors (10 mM tetrasodium pyrophosphate 200 μM sodium orthovanadate, and 10 mM sodium fluoride). NADPH oxidase-inhibitor DPI (diphenyleneiodonium chloride) (10 μM) and Nacetyl-L-cysteine (NAC) (20 mM) were from Sigma.
Determination of Cell Death
Cell death was assessed using a propidium iodide (PI, Sigma-Aldrich) [57] . Briefly, shortly after treatments in 24-well plates, 30 μM PI was added to each well. PI fluorescence was measured using a FL600 Microplate Fluorescence Reader (BioTeck). Spectrofluorometer analysis and settings were as follows: 530-nm excitation, 645-nm emission, and data were recorded in relative fluorescence units. As an index of cell death that was not related to actual differences between samples, baseline fluorescence F 1 was measured 1 h after addition of PI. Subsequent fluorescence readings were taken at several time points (F n ) after the onset of the experiment, keeping the cells in the incubator between measurements. Finally, the cells were permeabilized for 10 min at 37°C with 500-μM digitonin (Sigma Aldrich) to obtain the maximum fluorescence (100 % of cell death or F max ). The percentage of cell death (%CD) was calculated as follows: %CD = 100 × (F n − F 1 )/(F max − F 1 ) [57] .
Western Immunoblot
Samples from different sources were processed for western blot, including human post-mortem samples, mice cortical extract, and cultured cells. The collected samples were homogenized in (10 % w/v) of 50 mM Tris-HCl, pH 7.4/ 150 mM NaCl/0.5 % Triton X-100/0.5 % Nonidet P-40 and a mixture of protease inhibitor cocktail (Roche) and phosphatase inhibitors (10 mM tetrasodium pyrophosphate, 200 μM sodium orthovanadate, and 10 mM sodium fluoride). After this, the samples were centrifuged at 15,000×g for 20 min at 4°C. The resulting supernatant was normalized for protein content using BCA kit (Pierce). Cell extracts were boiled at 96°C for 3 min, followed by 6 % SDS electrophoresis, and electro-transferred to nitrocellulose membranes for 2 h at 4°C. Membranes were then blocked with 5 % non-fat milk in 0.1 M Tris-buffered saline (pH 7.4) for 2 h and incubated overnight in 0.5 % blocking solution containing primary antibodies. After incubation with peroxidase-tagged secondary antibodies (1:2000 diluted), the membranes were revealed by ECL-plus chemiluminescence western blot kit (Amershan-Pharmacia Biotech). In our experiments, each nitrocellulose membrane was used to detect reelin (4G10, Millipore), ApoER2 (Milipore), VLDL (MIllipore), β-actin (1:10,000; Sigma), or tubulin (1:5000; Sigma) PrP C levels. For Dab1 immunoprecipitation, 1000 μg of total protein was incubated with αDab1 (Exalpha Biologicals, Watertown, MA, USA) at 4 μg in 500-μl total volume overnight at 4°C. Afterward, immune complexes were precipitated using Protein-G-Sepharose (Amersham-Pharmacia Biotech; Barcelona, Spain) at 4°C for 90 min. After centrifugation, proteins were eluted in twice-concentrated Laemmli sample buffer at 96°C for 5 min, followed by 10 % SDS-PAGE and immunoblotting u s i n g t h e a n t i -p h o s p h o t y r o s i n e 4 G 1 0 ( U p s t a t e Biotechnology Inc., NY, USA). The membranes were reprobed with ab7522 antibody for total Dab1 detection (Abcam, Cambridge, MA, USA) [49, 50] .
Quantitative Real-Time Polymerase Chain Reaction
Quantitative real-time PCR was performed on total RNA extracted with mirVana's isolation kit (Ambion, Austin, TX, USA) from the cortex of CJD patients or from Tg340 mice. Purified RNAs were used to generate the corresponding cDNAs, which served as PCR templates for mRNA quantification. Two different sets of primers were used. First for the Tg340 mice, quantitative RT-PCR assays were performed in duplicate on cDNA samples obtained from the retrotranscription reaction diluted 1:20 in 384-well optical plates (Kisker Biotech, Steinfurt, GE) using the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems). The reactions were carried out using 20× TaqMan gene expression assays for genes and 2× TaqMan Universal PCR Master Mix (Applied Biosystems). The reactions were conducted using the following parameters: 50°C for 2 min, 95°C for 10 min, 40 cycles at 95°C for 15 s and 60°C for 1 min. The fold change was determined using the Eq. 2
−ΔΔCT
. Similar results were obtained using two different housekeeping genes for normalization (HPRT and GUSB). The assay numbers of RT-qPCR analysis were Mm00465200_m1 and Mm00465231_m1 for Reelin, Mm00446968_m1 for HPRT, and Mn00446958_g1 for the GUSB housekeeping genes.
For the human CJD samples, PCR amplification and detection were performed with the ROCHE LightCycler 480 detector, using 2× SYBR GREEN Master Mix (Roche) as reagent, following the manufacturer's instructions. The reaction profile was denaturation-activation cycle (95°C for 10 min) followed by 40 cycles of denaturation-annealing-extension (95°C for 10 min, 72°C for 1 min, 98°C continuous). mRNA levels were calculated using the LightCycler 480 software. Data were analyzed with SDS 1.9.1 software (Applied Biosystems) following the 2 −ΔΔCT method of Applied Biosystems. Primers were as follows: Reln (5′-actctgtcaacagctcaagc-3′) and (5′-tggtcaattgcccagctttg-3′). The results were normalized for the expression levels of the housekeeping gene, gapdh (5′-aggtcggtgtgaacggatttg-3′) and (5′-tgtagaccatgtagttgaggtca-3′), which were quantified simultaneously with the target gene [58] .
Immunohistochemistry and In Situ Hybridization
In situ hybridization was carried out as described previously [59] on 40-μm frozen adult brain sections. Both sense and antisense riboprobes were labeled with digoxigenin according to the manufacturer's instructions (Roche Farma). For the immunohistochemistry studies of frozen brain sections, tissue was incubated with primary antibodies overnight, followed by appropriate secondary antibodies. Tissue binding primary antibody was detected using the ABC method. Briefly, free-floating sections were rinsed in 0.1 M PBS, and endogenous peroxidase activity was blocked by incubation in 3 % H 2 O 2 and 10 % methanol dissolved in 0.1 M PBS. After extensive rinsing, sections were incubated in 0.1 M PBS containing 0.2 % gelatin, 10 % normal goat serum, 0.2 % glycine, and 0.2 % Triton-X 100 for 1 h at room temperature. Afterward, sections were incubated for 24 h at 4°C with the primary antibody: α-calbindin and α-parvalbumin (1:2000 diluted; Swant Antibodies, Switzerland). After that, sections were incubated with secondary biotinylated antibodies (2 h, 1:200 diluted) and streptavidin-horseradish peroxidase complex (2 h, 1:400 diluted). Peroxidase activity was revealed with 0.025 % diaminobenzidine (DAB) and 0.003 % hydrogen peroxide. After rinsing, sections were mounted onto slides, dehydrated, and cover-slipped with Eukitt™ (Merck). Samples were photo-documented using an Olympus BX61 microscope equipped with a cooled digital DP72L camera. For cell counting, the radial distribution of Reln-, calbindin-, or parvalbumin-positive cells was analyzed. Positive cells in individual layers were counted with a ×20 objective in 500-μm thick vertical strips covering the entire radial extent of the neocortex. 
Densitometry and Statistical Processing
For quantification, developed films were scanned at 2400 × 2400 dpi (i800 MICROTEK high-quality film scanner), and the densitometric analysis was performed using Quantity One Image software analysis (Biorad, Windows) and the Gel-Pro analyzer (Media Cybernetics, Windows). Statistical analysis of the obtained data was performed using Bonferroni post hoc test (Multiple comparison test) using GraphPad Prism 5.0c (Mac OsX, Grahpad). Data are presented as mean ± standard error of the mean (S.E.M.). Differences between groups were considered statistically significant at *P < 0.05.
Results
Adult Cortical Levels of Reelin Are Not Modified by Changes in Prnp Dosage
Endogenous levels of Prnp are reduced around 50 % in CJD patients [60] . This differs from what is reported in infected mice [61] . Therefore, we aimed to determine putative changes in the presence of Reelin in CJD patients and infection models and to determine whether Prnp expression levels correlated with changes in Reelin protein levels (Fig. 1) , and Tga20 mice were processed for reelin detection with western blotting (Fig. 1a, b) . (Fig. 1b) . Next, we aimed to corroborate these results by analyzing Reln mRNA expression in the neocortex of Prnp 0/0 and Prnp +/+ with in situ hybridization (Fig. 1c-e) . Qualitative (Fig. 1c, d ) and quantitative (Fig. 1e ) data corroborated that there were no relevant differences in the Reln mRNA expression between the two genotypes.
Increased Reelin Expression in PrP (106-126) -Treated Primary Cortical Neurons Does Not Correlate with Activation of the Reelin Pathway
Peptides mimicking prion sequences (e.g., human or mouse) have been used as models of prion-mediated cytotoxicity for many years [62] [63] [64] [65] . Thus, we aimed to check the effects of PrP in modifying Reelin protein levels in primary cortical neurons (Figs. 2 and 3) . First, to avoid the effects associated with low endogenous expression of PrP C levels, these were determined in primary cortical cultures at several days in vitro (DIV) in order to establish the appropriate time window for treatments ( Supplementary Fig. 1 ). Reasonable levels of PrP C in cultures were detected after 12-15 days in vitro ( Supplementary Fig. 1 ). In a second set of experiments, cortical neurons were maintained in vitro for 15 DIVand incubated with 80 μM aggregated PrP [66] for 30 min, 1 day, and 4 days, and Reelin expression levels were analyzed (Figs. 2a and 3) . Parallel cultures were incubated with scrambled peptide, 0.1 M PBS, untreated as internal controls (Fig. 2a) . In addition, levels of Dab1 phosphorylation were also checked after PrP (106-126) treatment (Fig. 3) . Results indicate that in the treated cultures, the upper band of 420 kD and the lower band of 180 kD of cellular Reelin could be easily distinguished in protein extracts (Fig. 2a and 3) . In addition, they showed a 1.25-fold increase in total Reelin at 24 h after PrP (106-126) treatment (P < 0.05, t = 2.819, 95 % confidence interval of diff. = −08.699 to 0.04990 (1 vs 1 day + PrP (106-126) )); ANOVA Bonferroni post hoc test (Fig. 3) . This Reelin increase can be seen, albeit reduced, 4 days after treatment (1.21-fold increase) (P < 0.05, t = 3249, 95 % confidence interval of diff. = −0.7222 to −0.009744 (4 vs 4 day + PrP (106-126) ) ANOVA Bonferroni post hoc test) (Fig. 3) . Surprisingly, this increase in Reelin is delayed with respect to the increase in p-Dab1 and degradation (Fig. 3) . Indeed, increased p-Dab1 was observed shortly after 30 min of incubation with PrP (106-126) (Fig. 3) . This happens prior to the Reelin increase (24 h) suggesting that early Dab1 phosphorylation is not mediated by Reelin (Fig. 3) . In addition, this data suggests that these changes in Reelin do not correlate with increased Reelin-mediated signaling. This was also corroborated by analyzing ApoER2 levels [67] . Changes in ApoER2 levels are modulated by Reelin signaling [67] . However, ApoeR2 and VLDLR levels remained constant during these periods, except after 4 days in vitro, they were slightly changed without reaching statistical signification (Fig. 2b) . Quantification of ApoeR2/Actin ratio was 0.62 ± 0.02 (untreated) vs 0 . 4 1 ± 0 . 0 9 ( P r P ( 1 0 6 -1 2 6 ) ) 1 d a y o f t r e a t m e n t (mean ± S.E.M.) and 0.34 ± 0,03 (untreated) vs 0.59 ± 0.09 (PrP (106-126) ) 4 days of treatment (mean ± S.E.M.). Quantification of VLDLR/Actin ratio was 0.69 ± 0.06 ( u n t r e a t e d ) v s 0 . 4 9 ± 0 . 0 9 1 d a y o f t r e a t m e n t (mean ± S.E.M.) and 0.53 ± 0.06 (untreated) vs 0.70 ± 0,10; 4 days of treatment (mean ± S.E.M.). Changes after 4 days might reflect changes in cell death due to the amyloid treatment. In fact, a higher level of cell death was monitored by using propidium iodide uptake in PrP -treated cultures (Fig. 2e) . Next, in order to determine whether the fast Dab1 phosphorylation observed after peptide treatment is related with Reelin, we processed primary neuronal cultures obtained from reeler mice. Treatment of reeler-derived cortical neurons lacking reelin with PrP (106-126) is also able to increase p-Dab1 (0.293 ± 0.0159 (scrambled) vs 0.498 ± 0.033 (PrP (106-126) ), mean ± S.E.M., P < 0.05, t = 3.381, 95 % confidence interval of diff. = −0.398 to −0.010; ANOVA Bonferroni post hoc test) (Fig. 2c, d) , reinforcing the notion that the presence of reelin is not mandatory in the increased p-Dab1 levels mediated by PrP . Increased kinase activity and high levels of ROS have been described after prion infection [33, 66, [68] [69] [70] and in sCJD patients [33] . Thus, we aimed to explore whether ROS generation in treated cultures participates in the observed changes in Reelin expression. Results showed that the ROS scavenger NAC and the NADPH oxidase inhibitor DPI are able to block Reelin increase mediated by PrP (106-126) (Fig. 2f) .
Decreased Reelin Protein Levels in Prion-Inoculated Mice
Prnp +/+ were inoculated with 22L or Mo-BSE prions, and cortical levels of Reelin were determined in cortical extracts of terminal mice (137-138 days (22L) and 201-202 days (Mo-BSE)). Developed film demonstrated a decrease in Reelin levels in 22L-inoculated mice (0.5360 ± 0.028 (noninoculated) vs 0.2990 ± 0.055 (22L inoculated), mean ± S.E.M., P < 0.05, t = 4.943; 95 % confidence interval of diff. = 0.1188 to 0.4091; ANOVA Bonferroni post hoc test) (Fig. 4) . Mo-BSE-inoculated mice also showed reduced Reelin content compared to non-inoculated mice (0.3510 ± 0.026 (Mo-BSE inoculated), mean ± S.E.M., P < 0.05, t = 3.602; 95 % confidence interval of diff. = 0.0525 to 0.3755 (Fig. 4) . This decrease in Reelin could be due to a decrease in Reelin-expressing cells in affected brains. Thus, terminal prion-inoculated mice (Prnp +/+ ) and time-matched Prnp 0/0 inoculated mice were histologically processed to Reln with in situ hybridization (Fig. 5) . Cell counts of revealed sections demonstrated that neither the distribution nor the total number of Reln-positive cells was significantly modified in the neo cortex of the inoculated mice compared with the controls (Fig. 5) . As Reelin is expressed mainly by cortical interneurons in adult cortex (mainly in calbindin, calretinin, NPY-, and somatostatin-but rarely on parvalbumin-, cholecystokinin-, or VIP-positive interneurons) [71] , we also analyzed the number of calbindin-and parvalbumin-positive interneurons in the neocortex of inoculated and control mice. Results showed similar numbers of calbindin-positive cells in inoculated and non-inoculated mice (Fig. 5b-h) . In contrast, the number of parvalbumin-positive cells decreased slightly (≈16.3 %) in layers IV-VI of Prnp +/+ -inoculated mice (Fig. 5c-i ) corroborating previous results [72] . Taken together, these results indicate that a direct effect of changes in Reelin protein levels on non-pyramidal neuron populations in inoculated mice is unlikely.
Changes in Reelin Expression in CJD Post-Mortem Samples and CJD-Inoculated Mice
Total levels of Reelin and Reln mRNA changes were analyzed in human post-mortem samples of frontal cortex of CJD patients (Tables 1 and 2 ; Fig. 6 ). Although the data did not reach a P value <0.05 (Type II vs control; t = 0,6165; 95 % confidence interval of diff. = −0.312 to 0.421; ANOVA Bonferroni post hoc test), the results indicated a tendency of higher level of Reelin in CJD patients, especially in type II (5.450 ± 0.490 (type II) vs 4.973 ± 0.490 (type I) vs 4.203 ± 0.4214 (control)) (Fig. 6b ). This tendency in CJD patients was also corroborated (Fig. 6c) . In parallel, we also aimed to determine mRNA levels of Reln in the cerebral cortices of Tg340 mice inoculated with human Met/Met PrP type 1 inoculum (Fig. 6d) . Tg340 mice inoculated with sCJD showed a faster evolution of the infective process (around 180 days post-inoculum (DPi)) than 22L in Mo-BSE infected mice). In addition, they showed increased levels of Reln mRNA at these days post-inoculation (Fig. 6 d) (0.1245 ± 0.013 (Con) vs 0.2210 ± 0.026 (CJD); mean ± S.E.M., 1.71 ± 0.23-fold increase; P = 0.0141; t = 3.248; 95 % confidence interval of diff. = − 0.79 to 0.244). In previous DPi, asymptomatic mice (120 DPi) or those with few symptoms (160 DPi), levels of Reelin were identical to control mice (Fig. 6d) . Unfortunately, processing of paraffin-embedded Tg340 mice or post-mortem (CJD) human samples with formic acid impairs the use of current antibodies against Reelin or Reln mRNA detection to expand these biochemical data histologically.
Discussion
The glycoprotein Reelin plays relevant roles during development, maturation, and adult synapse maintenance of the nervous system. In addition, it plays a neuroprotective role in Alzheimer's disease against β-amyloid-associated cytotoxicity [12, 47] . Unfortunately, its presence in brain parenchyma decreases during normal development, aging, and neurodegeneration [36, 41, 42] . In addition, in Alzheimer's disease, Reelin seems not to be functional when generated in the presence of β-amyloid [46, 73] . Thus, Reelin-dependent induction of Dab1 phosphorylation appeared reduced in the presence of β-amyloid being unable to modulate the cleavage of ApoER2 [46] .These functional changes in Reelin are likely associated to changes in Reelin glycosylation [37] . These changes compromise its capacity to bind to ApoER2, impeding the ability to decrease tau phosphorylation [46, 73] . A reduced Reelin expression is associated with impaired signaling, resulting in cognitive decline [24, 74] . Blockage of reelin signaling is sufficient to impair memory [75] . Thus, impaired Reelin signaling could contribute to the clinical symptoms and pathological progression in neurodegeneration.
Although Reelin expression levels have been characterized in some neural diseases (see the BIntroduction^section for references), no data have been published on natural TSEs or on models of prion infection. Bearing this in mind, we sought to determine whether Reelin levels changed in TSEs and to check their putative changes as a putative diagnostic biomarker of prion diseases. First, we determined that levels of Reelin were not modified with different doses of Prnp. This contrasts with a decrease in Reelin in brain extracts of Prnp 0/0 mice reported by Devanathan and co-workers [76] . This difference could be associated with the use of Zürich I Prnp 0/0 mice [76] in contrast to C57Bl6/J backcrossed B6.129 mice with lower 129Sv loci (our study; see also [77, 78] for details). In fact, we determined that adult Reln mRNA levels were not modified between Prnp
, and Tga20 mice in a previous study [77] as also observed by [79] . Our results indicate that Reelin increased in primary cultures when treated with 80 μM aggregated peptides mimicking human PrP C , in post-mortem cortical samples of CJD patients and in the neocortex of infected mice with sCJD type I inoculum. In contrast, mice inoculated with 22L and Mo-BSE prions showed decreased Reelin levels. In this respect, although a clear explanation is not yet available, differences between mouse prion diseases (22L and Mo-BSE) and sCJD in both human and Tg340 mice could be related to prion strain properties. In fact, similar differences between mice and human TSEs have also recently been reported for Tau content and its phosphorylated form [80] . On the other hand, a recent study reported that Tau, and more specifically p-Tau levels, decreased in brain parenchyma of CJD patients [60] . Reelin acting through Dab1 phosphorylation increases Akt-Pi3K activation, decreasing GSK3β activity and levels of p-Tau [18, 19] . Thus, it is reasonable to consider that increased levels of Reelin (if functional) in CJD patients (type I and II of PrP) may contribute to maintaining or decreasing levels of p-Tau.
With respect to the in vitro data, we were surprised by the increase in Reelin after peptide treatment, and so we checked previous reported data using similar cultures. It is well known that primary cultures treated with 80 μM PrP show activated Akt [66] . However, Simon et al. reported decreased activity of PI3K and Akt in the cerebellum of inoculated mice and neuronal cultures after PrP (106-126) (40 μM) incubation [81, 82] , as we found with lower doses of PrP [66] . In our experience, these differences are likely to be associated with the handling, preparation, and concentration of the PrP (106-126) used for the experiments. High concentrations of PrP increase ROS production in treated cells (Fig. 2 ) (see also [66, 69, 83] ). In this study, we showed that the increase in Reelin after PrP incubation could be linked to a burst of ROS production induced by the peptide. ROS increase runs in parallel to the relevant kinase activation reported after the inoculation of (263 K) [33] or RML [48, 66] prions as well as human prion peptides [66, 68] . In addition, our results also point the need of different approaches (in vivo and in vitro) to analyze prion-derived effects. For example, human-derived peptides are able to induce Dab1 phosphorylation in Reln-derived neurons. Further studies are needed to ascertain the molecular actor/s involved and other kinases are able to increase Dab1 phosphorylation in the absence of reelin as described during development [84] .
Due to that mRNA and protein levels in CJD and sCJDinfected mice only occur at the final stages of the disease, we believe that the increased Reelin changes are likely associated with the profound metabolic changes (e.g., cellular stress, inflammation, etc.) strongly present in the last stages of the infective process. In addition, this invites the question of whether the increased Reelin levels observed in CJD and Tg340 mice also correspond to a Bnon-functional^protein has indicated in AD. In fact, low Dab1 phosphorylation is observed in sCJD PrP type II in the presence of the highest levels of Reelin observed in the study (see [50] for description) and levels of p-Tau (normally decreased by functional Reelin) were higher in similar sCJD samples [60, 85] .
Levels of p-Tau and Tau have been suggested as a potential biomarker in prionopathies such as the 14-3-3 protein [60, 85, 86] . Reln was associated as a susceptible gene in Alzheimer's disease but not in Parkinson's disease [87] . However, increased levels of a Reelin band of 180 kD have been determined in CSF of AD, Parkinson's disease [37] , and frontotemporal dementia [38] . In these neurodegenerative diseases, whether it is the case that Reelin participates in the onset of the disease or its alteration is a secondary effect of the neurodegeneration still remains elusive. Thus, with the present results, it is reasonable to consider that observed changes in Reelin at advanced stages of the prionopathies are secondary to the degenerative process and are probably associated with the physiological changes observed in the disease [88, 89] . In conclusion, Reelin increase is not associated with the processes linked to early onset of disease and is therefore not a potential biomarker for prionopathies.
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